JP2023512758A5 - - Google Patents
Info
- Publication number
- JP2023512758A5 JP2023512758A5 JP2022547680A JP2022547680A JP2023512758A5 JP 2023512758 A5 JP2023512758 A5 JP 2023512758A5 JP 2022547680 A JP2022547680 A JP 2022547680A JP 2022547680 A JP2022547680 A JP 2022547680A JP 2023512758 A5 JP2023512758 A5 JP 2023512758A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- guide rna
- guide
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971906P | 2020-02-07 | 2020-02-07 | |
| US62/971,906 | 2020-02-07 | ||
| US202062981965P | 2020-02-26 | 2020-02-26 | |
| US62/981,965 | 2020-02-26 | ||
| US202063019076P | 2020-05-01 | 2020-05-01 | |
| US63/019,076 | 2020-05-01 | ||
| PCT/US2021/016730 WO2021158858A1 (en) | 2020-02-07 | 2021-02-05 | Compositions and methods for kallikrein ( klkb1) gene editing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512758A JP2023512758A (ja) | 2023-03-29 |
| JP2023512758A5 true JP2023512758A5 (enExample) | 2024-02-14 |
Family
ID=74873798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022547680A Pending JP2023512758A (ja) | 2020-02-07 | 2021-02-05 | カリクレイン（ｋｌｋｂ１）遺伝子編集のための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20230295587A1 (enExample) |
| EP (1) | EP4100528A1 (enExample) |
| JP (1) | JP2023512758A (enExample) |
| KR (1) | KR20220139352A (enExample) |
| CN (1) | CN115362256A (enExample) |
| AU (1) | AU2021216451A1 (enExample) |
| BR (1) | BR112022015380A2 (enExample) |
| CA (1) | CA3169813A1 (enExample) |
| CL (1) | CL2022002095A1 (enExample) |
| CO (1) | CO2022012196A2 (enExample) |
| IL (1) | IL295280A (enExample) |
| MX (1) | MX2022009658A (enExample) |
| PH (1) | PH12022552009A1 (enExample) |
| SA (1) | SA522440054B1 (enExample) |
| WO (1) | WO2021158858A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12042509B2 (en) | 2021-10-01 | 2024-07-23 | Adarx Pharmaceuticals, Inc. | Prekallikrein-modulating compositions and methods of use thereof |
| WO2023086953A1 (en) * | 2021-11-11 | 2023-05-19 | Beam Therapeutics Inc. | Compositions and methods for the treatment of hereditary angioedema (hae) |
| TW202346586A (zh) * | 2022-01-28 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法 |
| WO2024011206A1 (en) * | 2022-07-08 | 2024-01-11 | Intellia Therapeutics, Inc. | Methods for in vivo editing of klkb1 |
| WO2024012435A1 (en) * | 2022-07-11 | 2024-01-18 | CorrectSequence Therapeutics Co., Ltd | Gene editing systems and methods for treating hereditary angioedema |
| WO2025096980A1 (en) * | 2023-11-02 | 2025-05-08 | Poseida Therapeutics, Inc. | Compositions targeting klkb1 and methods of use thereof |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| CN118303422B (zh) * | 2024-04-17 | 2024-11-12 | 华南师范大学 | Ppk基因在控制德国小蠊繁殖行为中的应用 |
| WO2026008078A1 (en) * | 2024-07-05 | 2026-01-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Methods for kallikrein (klkb1) gene editing |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| JP3131222B2 (ja) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | ギャップを有する２′修飾オリゴヌクレオチド |
| JPH10500310A (ja) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ |
| EP3320922A1 (en) * | 2011-06-10 | 2018-05-16 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| DK2931891T3 (da) | 2012-12-17 | 2019-08-19 | Harvard College | Rna-styret modificering af menneskelige genomer |
| KR102365486B1 (ko) * | 2013-08-28 | 2022-02-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 프리칼리크레인 (pkk) 발현의 조절 |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP3083556B1 (en) * | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| HUE052709T2 (hu) * | 2014-05-01 | 2021-05-28 | Ionis Pharmaceuticals Inc | Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására |
| WO2015200555A2 (en) | 2014-06-25 | 2015-12-30 | Caribou Biosciences, Inc. | Rna modification to engineer cas9 activity |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| JP6695902B2 (ja) * | 2015-05-06 | 2020-05-20 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| WO2017136794A1 (en) | 2016-02-03 | 2017-08-10 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| US20180112234A9 (en) * | 2016-03-14 | 2018-04-26 | Intellia Therapeutics, Inc. | Methods and compositions for gene editing |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| CA3035534A1 (en) * | 2016-09-07 | 2018-03-15 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
| SG10202106058WA (en) | 2016-12-08 | 2021-07-29 | Intellia Therapeutics Inc | Modified guide rnas |
| EP3649243A1 (en) * | 2017-07-07 | 2020-05-13 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12) |
| WO2019067910A1 (en) | 2017-09-29 | 2019-04-04 | Intellia Therapeutics, Inc. | POLYNUCLEOTIDES, COMPOSITIONS AND METHODS FOR GENOMIC EDITION |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| AU2019282824C1 (en) | 2018-06-08 | 2026-04-23 | Intellia Therapeutics, Inc. | Modified guide RNAS for gene editing |
| US12521451B2 (en) * | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
-
2021
- 2021-02-05 BR BR112022015380A patent/BR112022015380A2/pt unknown
- 2021-02-05 CN CN202180026687.4A patent/CN115362256A/zh active Pending
- 2021-02-05 CA CA3169813A patent/CA3169813A1/en active Pending
- 2021-02-05 IL IL295280A patent/IL295280A/en unknown
- 2021-02-05 KR KR1020227030659A patent/KR20220139352A/ko active Pending
- 2021-02-05 EP EP21711973.4A patent/EP4100528A1/en active Pending
- 2021-02-05 WO PCT/US2021/016730 patent/WO2021158858A1/en not_active Ceased
- 2021-02-05 MX MX2022009658A patent/MX2022009658A/es unknown
- 2021-02-05 PH PH1/2022/552009A patent/PH12022552009A1/en unknown
- 2021-02-05 JP JP2022547680A patent/JP2023512758A/ja active Pending
- 2021-02-05 AU AU2021216451A patent/AU2021216451A1/en active Pending
-
2022
- 2022-08-03 CL CL2022002095A patent/CL2022002095A1/es unknown
- 2022-08-04 SA SA522440054A patent/SA522440054B1/ar unknown
- 2022-08-05 US US17/882,099 patent/US20230295587A1/en not_active Abandoned
- 2022-08-26 CO CONC2022/0012196A patent/CO2022012196A2/es unknown
-
2023
- 2023-07-31 US US18/362,675 patent/US20240018496A1/en not_active Abandoned
-
2025
- 2025-01-17 US US19/028,692 patent/US12480109B2/en active Active
- 2025-09-17 US US19/331,096 patent/US20260022358A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512758A5 (enExample) | ||
| US12595485B2 (en) | Modulation of prekallikrein (PKK) expression | |
| KR102501980B1 (ko) | 화학적으로 변형된 단일 가닥 rna-편집 올리고뉴클레오타이드 | |
| UA130104C2 (uk) | Композиції на основі ліпідних наночастинок | |
| JP2022544702A (ja) | スプライシングおよびタンパク質発現を調節するための組成物および方法 | |
| JP2009537129A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
| EP4647124A2 (en) | Therapeutics for the treatment of neurodegenerative disorders | |
| EP3128008A2 (en) | Novel double-stranded oligo rna and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases | |
| CA2795145A1 (en) | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 | |
| JP2010532163A5 (enExample) | ||
| CN119998446A (zh) | 用于靶向pcsk9的组合物和方法 | |
| KR20190134506A (ko) | 엠피레귤린 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 | |
| CA3067333A1 (en) | Enzymatic replacement therapy and antisense therapy for pompe disease | |
| US20250290073A1 (en) | Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing | |
| KR20180057608A (ko) | 치료용 올리고뉴클레오타이드 | |
| US12480127B2 (en) | siRNA, medical compositions, and methods for treating diabetes using the same | |
| CA3191765A1 (en) | Closed-ended dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) | |
| US8450473B2 (en) | Compositions and methods for therapy of macular degeneration | |
| JP7760130B2 (ja) | Ａｐｏｃ３を標的としたアンチセンス核酸 | |
| JP2024524974A (ja) | ナンセンス変異依存ｒｎａ分解機構に基づく病態及び疾患の処置のためのアンチセンスオリゴマー | |
| EP4063504A1 (en) | Ctgf gene-specific double-stranded oligonucleotide, and a composition for preventing and treating fibrotic diseases and respiratory-related diseases comprising same | |
| JP2025520199A (ja) | 発現を調節するための薬剤 | |
| CN115551519A (zh) | 用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法 | |
| CN114126668A (zh) | 用于血色素沉积症治疗的组合物和方法 | |
| CN117925623B (zh) | 用于hao1基因编辑和治疗ph1的组合物 |